WASHINGTON DC—Gene expression and molecular pathways in head and neck cancer have been identified with reference to The Cancer Genome Atlas in research presented at the American Association for Cancer Research annual conference. The PIK-3CA pathway and P 53 gene mutation were named as significant players in head and neck cancers by Dr David Neil Hayes of the Lineberger Cancer Center at the University of North Carolina in Chapel Hill. He told Peter Goodwin how his group’s analysis of tumour samples from patients with head and neck cancer have provided knowledge of disease mechanisms — revealing the need to individualise therapy with drugs such as epidermal growth factor receptor inhibitors.
You may also like...
Rituximab Maintenance Cuts Follicular Lymphoma Recurrence Risk In Half — Phase III PRIMA Study Results 28 Jun, 2010 ASCO Audio Journal of Oncology – September 15th, 2006 14 Sep, 2006 Oncology Times Broadcast News with the Audio Journal of Oncology – Bilateral Prophylactic Mastectomy For DCIS 6 Apr, 2009 Breast Cancer: Further Support for Trastuzumab from Combined Analysis 30 Oct, 2005
- Previous story Chimeric antigen receptor T-cell therapy rescues kids with relapsing acute lymphoblastic leukaemia
- Next story Blood test reliably detects cancer mutations in gastrointestinal stromal tumour
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014